0000950170-24-026885.txt : 20240306 0000950170-24-026885.hdr.sgml : 20240306 20240306091559 ACCESSION NUMBER: 0000950170-24-026885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240206 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Apeiron Presight Capital Fund II, L.P. CENTRAL INDEX KEY: 0001840676 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24724525 BUSINESS ADDRESS: STREET 1: 340 S LEMON AVE #3391 CITY: WALNUT STATE: CA ZIP: 91789 BUSINESS PHONE: 4156382393 MAIL ADDRESS: STREET 1: 340 S LEMON AVE #3391 CITY: WALNUT STATE: CA ZIP: 91789 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Apeiron Investment Group Ltd. CENTRAL INDEX KEY: 0001845711 ORGANIZATION NAME: STATE OF INCORPORATION: O1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24724526 BUSINESS ADDRESS: STREET 1: BLOCK A, APT.12 STREET 2: IL-PIAZZETTA, TOWER ROAD CITY: SLIEMA STATE: O1 ZIP: SLM1605 BUSINESS PHONE: 44 7557 251 563 MAIL ADDRESS: STREET 1: BLOCK A, APT.12 STREET 2: IL-PIAZZETTA, TOWER ROAD CITY: SLIEMA STATE: O1 ZIP: SLM1605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Angermayer Christian CENTRAL INDEX KEY: 0001845872 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24724524 MAIL ADDRESS: STREET 1: BLOCK A, APT.12 STREET 2: IL-PIAZZETTA, TOWER ROAD CITY: SLIEMA STATE: O1 ZIP: SLM1605 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 4 1 ownership.xml 4 X0508 4 2024-02-06 true 0001999480 Alto Neuroscience, Inc. ANRO 0001845711 Apeiron Investment Group Ltd. 66 & 67 AMERY STREET SILEMA O1 SLM1707 MALTA false false false true See Remarks 0001840676 Apeiron Presight Capital Fund II, L.P. 66 & 67 AMERY STREET SILEMA O1 SLM 1707 MALTA false false false true See Remarks 0001845872 Angermayer Christian 66 & 67 AMERY STREET SILEMA O1 SLM 1707 MALTA false false false true See Remarks false Common Stock 2024-02-06 4 C false 251881 A 251881 D Common Stock 2024-02-06 4 C false 674658 A 674658 I By Apeiron Presight Capital Fund II, L.P.( Warrants to Purchase Series A Preferred Stock 2024-02-06 4 C false 444561 D Common Stock 69304 0 D Series A Preferred Stock 2024-02-06 4 C false 406072 D Common Stock 182577 0 D Series A Preferred Stock 2024-02-06 4 C false 1063918 D Common Stock 478359 0 I By Apeiron Presight Capital Fund II, L.P. Series B Preferred Stock 2024-02-06 4 C false 416665 D Common Stock 196299 0 I By Apeiron Presight Capital Fund II, L.P. In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. The Form 3 filed by the Reporting Persons on February 2, 2024 inadvertently included securities Apeiron SICAV Ltd. The Reporting Persons do not have voting or dispositve power over such securities and disclaim any beneficial ownership of such securities. As a result of foregoing, the Reporting Persons were inadvertently characterized as 10% owners. Apeiron Investment Group Ltd. By: /s/ Julien Hoefer, Director 2024-03-05 Apeiron Presight Capital Fund II, L.P. By: /s/ Julien Hoefer, Director 2024-03-05 /s/ Christian Angermayer 2024-03-05